Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone617-401-9000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.94 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine Inc (NASDAQ:EDIT) posted its quarterly earnings data on Thursday, February, 28th. The company reported ($0.52) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.04. The business had revenue of $6.12 million for the quarter, compared to analyst estimates of $16.30 million. Editas Medicine had a negative return on equity of 46.82% and a negative net margin of 344.28%. View Editas Medicine's Earnings History.
When is Editas Medicine's next earnings date?
What price target have analysts set for EDIT?
7 brokerages have issued twelve-month price objectives for Editas Medicine's shares. Their forecasts range from $30.00 to $55.00. On average, they expect Editas Medicine's stock price to reach $40.25 in the next year. This suggests a possible upside of 78.0% from the stock's current price. View Analyst Price Targets for Editas Medicine.
What is the consensus analysts' recommendation for Editas Medicine?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Editas Medicine.
Has Editas Medicine been receiving favorable news coverage?
News stories about EDIT stock have been trending somewhat negative on Saturday, according to InfoTrie. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Editas Medicine earned a news impact score of -1.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Regenxbio (RGNX), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD) and Orchard Therapeutics (ORTX).
What other stocks do shareholders of Editas Medicine own?
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Ms. Katrine S. Bosley, Pres & CEO (Age 51)
- Dr. Andrew A. F. Hack, Chief Financial Officer (Age 45)
- Dr. Charles Albright, Chief Scientific Officer (Age 61)
- Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
- Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 65)
When did Editas Medicine IPO?
(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Who are Editas Medicine's major shareholders?
Editas Medicine's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.70%), FMR LLC (2.69%), Ontario Teachers Pension Plan Board (1.82%), Northern Trust Corp (1.14%), Geode Capital Management LLC (1.06%) and Geode Capital Management LLC (1.06%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman and Vickesh Myer. View Institutional Ownership Trends for Editas Medicine.
Which major investors are selling Editas Medicine stock?
EDIT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, First Trust Advisors LP, Hudson Bay Capital Management LP, Global Thematic Partners LLC, WS Management Lllp, Jane Street Group LLC, Bank of America Corp DE and Great West Life Assurance Co. Can. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright, Katrine Bosley and Vickesh Myer. View Insider Buying and Selling for Editas Medicine.
Which major investors are buying Editas Medicine stock?
EDIT stock was purchased by a variety of institutional investors in the last quarter, including Ontario Teachers Pension Plan Board, American Century Companies Inc., Norges Bank, Two Sigma Investments LP, BlackRock Inc., 361 Capital LLC, Millennium Management LLC and SHANDA ASSET MANAGEMENT HOLDINGS Ltd. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.
How do I buy shares of Editas Medicine?
Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of EDIT stock can currently be purchased for approximately $22.61.
How big of a company is Editas Medicine?
Editas Medicine has a market capitalization of $1.11 billion and generates $31.94 million in revenue each year. The company earns $-109,950,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.
What is Editas Medicine's official website?
How can I contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]
MarketBeat Community Rating for Editas Medicine (NASDAQ EDIT)
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
